COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of December 20, 2021
Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.
The CDC Recommends Pfizer, Moderna COVID Vaccines over J&J
The CDC recommends against the J&J COVID-19 vaccine if Pfizer or Moderna mRNA shots are available while affirming that any COVID vaccine is better than none.
Continuous Glucose Monitoring for Type 2 Diabetes in Primary Care: 2021 Research Review
Continuous glucose monitoring for type 2 diabetes patients is gaining exposure in the literature with positive evidence accumulating. Examples follow.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of December 16, 2021
Racial Disparities in Use of Diabetes Technology Widen among Medicare Enrollees
While use of insulin pumps and CGM increased over a 3-year study period for all racial-ethnic groups, the inequities were significant between White adults and all others.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of December 15, 2021
Pop Flu Quiz: What does the CDC say?
The CDC recommends ASAP use of antivirals in certain high-risk patient groups. Test your memory of who is in those groups with 2 short questions.
Finerenone Reduces Risk of Incident HF in Patients with T2D + CKD in FIGARO-DKD Analyses
Finerenone, the nonsteroidal mineralocorticoid receptor antagonist, significantly reduced new-onset HF and improved other HF outcomes in the FIGARO-DKD trial.
Lipids, Atherosclerosis, & Thrombosis: A Cardiometabolic Disease Quiz
When is aspirin appropriate in primary ASCVD prevention? Should ezetimibe be added to maximal statin therapy in T2D? This quiz tests your guideline savvy.
Smoking Outcomes May Improve ASCVD Risk Prediction, Suggests New Analysis
In a new retrospective analysis, including smoking history in the 2013 ACC/AHA pooled cohort equations significantly improved ASCVD risk prediction.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of December 14, 2021
Pfizer COVID-19 Oral Antiviral Still Nearly 90% Effective Against Severe Disease
Pfizer reported today final results of the phase 2/3 EPIC-HR trial, findings that confirm the investigational drug's 89% efficacy against severe COVID-19 disease.
Persistent Dyspnea in Patients with Long COVID-19 May Indicate Heart Issues
New research presented at EuroEcho 2021 may help explain why some patients with long COVID-19 experience persistent dyspnea even 1 year after recovery.
Flu Called out by COVID as "Irrelevant," Flu Calls Press Conference, Issues Statement
COVID-19, in an attempt to bully Flu and potentially gain precious lung space in humans this year, provoked the veteran virus, labeling him as "irrelevant." Flu responds.
Flu Responds to COVID-19 Allegations: Press Conference Transcript
Influenza takes questions from key media outlets to rebut assertions by COVID-19 that Flu's heyday has come to an end. He replies to MSNBC, Fox News, CBS, & the Christian Science Monitor.
Excess Weight and Genetics May Put Women at Higher Risk of Gout
Excess adiposity and genetic predisposition both were found to be associated with a higher risk of gout, particularly among US women, in a new prospective study.
FDA Extends Pfizer-BioNTech COVID-19 Vaccine Booster EUA to Cover 16-17-year-olds
Referencing waning immunity of the 2-dose mRNA series and availability of the vaccine to youth in this age group for more than a year, FDA determined that benefits outweigh risks.
CARDIOLOGY: 2021 Clinical Focus Collection
AHA Scientific Sessions 2021 recap, tests of clinical knowledge, expert interviews, and more in this roundup from Patient Care Online.
Obesity Linked to Elevated Risk of Heart Failure in Persons with Diabetes
Increases in obesity parameters significantly increased risk of incident heart failure in persons with diabetes, but not without diabetes, in a large community-based cohort study.
Intranasal Zavegepant for Migraine Meets Coprimary Regulatory Endpoints in Pivotal Phase 3 Trial
Intranasal CGRP inhibitor zavegepant met coprimary regulatory endpoints in pivotal phase 3 trial in adults with migraine; FDA submission planned for Q1 2022.